Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript Summary
Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript Summary
General and administrative expenses decreased slightly to $6.8 million from $7.1 million in the previous year.The following is a summary of the Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript:
以下是鸚鵡螺體育生物技術公司（NAUT）2024年第三季度業績會交流會議紀要：
Financial Performance:
金融業績：
Total operating expenses for Q3 2024 remained flat year-over-year at $19.1 million.
Research and development expenses were $12.3 million in Q3 2024, mirroring the expense from the prior year.
General and administrative expenses decreased slightly to $6.8 million from $7.1 million in the previous year.
Net loss for Q3 2024 was $16.4 million, slightly higher than the $15.9 million in Q3 2023.
Cash, cash equivalents, and investments stood at approximately $221.2 million at the end of Q3 2024, a decrease from $232.9 million at the end of the previous quarter.
2024年第三季度的總營業費用與去年持平，爲1910萬美元。
2024年第三季度的研發費用爲1230萬美元，與前一年的費用相同。
總務費用從上年的710萬美元略微降至680萬美元。
2024年第三季度的淨虧損爲1640萬美元，略高於2013年第三季度的1590萬美元。
截至2024年第三季度，現金、現金等價物和投資約爲22120萬美元，較上一季度結束時的23290萬美元有所減少。
Business Progress:
業務進展：
Nautilus is advancing in the development of its proteomics platform, with significant progress in both broad scale discovery and targeted proteoform quantification.
The company has demonstrated the integration and functioning of various platform components necessary for comprehensive protein analysis, albeit some optimizations remain for commercial readiness.
Nautilus appointed Ken Suzuki as the Chief Marketing Officer to lead the go-to-market strategy for their innovative platform.
鸚鵡螺體育在其蛋白質組學平台的發展中取得了重要進展，無論是在廣泛規模的發現還是有針對性的蛋白形態定量方面。
公司已經展示了綜合蛋白質分析所需的各種平台元件的整合和作用，儘管一些優化工作尚需進行以達到商業就緒狀態。
鸚鵡螺體育任命Ken Suzuki爲首席營銷官，負責領導其創新平台的營銷策略。
Opportunities:
機會：
There is an increasing recognition of the role that proteomic analysis will play in biomedical research, heightening interest in Nautilus's proteomics platform among global researchers.
The company's ongoing advancement in targeted proteoform quantification broadens its potential application in drug development and biomarker discovery, particularly in neurodegenerative diseases with an initial focus on tau as a biomarker for Alzheimer's.
人們越來越認識到蛋白質組學分析在生物醫藥研究中的作用，這引起了全球研究人員對鸚鵡螺體育蛋白質組學平台的興趣。
公司在有針對性的蛋白形態定量方面不斷取得進展，拓寬了其在藥物開發和生物標誌物發現中的潛在應用，尤其在以tau作爲阿爾茨海默病生物標誌物爲初始焦點的神經退行性疾病領域。
Risks:
風險：
Nautilus reported falling behind on internal milestones for broad scale discovery due to challenges in getting affinity probes to meet performance targets, which could delay the expected commercial launch schedules.
High fallout rate of probe candidates from expected performance standards demands significant enhancements and optimizations, posing a risk to platform readiness and timeline.
鸚鵡螺體育報告稱，在蛋白質組的廣泛規模發現方面落後於內部里程碑，由於在使親和探針達到性能指標方面遇到了挑戰，這可能會延遲預期的商業推出時間表。
預期績效標準中探針候選的高脫落率要求進行重大增強和優化，這對平台準備和時間表構成風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
